{
  "Country": "DE",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "Sotorasib (targeted therapy).",
      "Comparator": "Other systemic therapies (not specified).",
      "Outcomes": "Response rate of 37.1%, median duration of response of 11.1 months, median progression-free survival of 6.8 months, and median overall survival of 12.5 months."
    }
  ],
  "SourceType": "clinical_guideline"
}